FHL2 and hypertrophic cardiomyopathy: Importantly we also showed that binding between nesprin-2/telethonin and nesprin-2/FHL-2 was impaired by nesprin-2, telethonin, and FHL-2 mutations identified in patients with EDMD with DCM and patients with hypertrophic cardiomyopathy (HCM), implicating these complexes as key to cardiac function.